Abstract. Although acute myeloid leukemia (AML) exhibits diverse responses to chemotherapy, patients harboring the t(8;21) translocation are part of a favorable risk group. However, the reason why this subgroup is more responsive to cytarabine-based therapy has not been elucidated. In the present study, we analyzed expression levels of cytarabine metabolism-related genes in patients diagnosed with AML with or without t(8;21) and investigated their correlation with clinical outcomes after cytarabine-based therapy. Among the 8 genes studied, expression of the concentrative nucleoside transporter 3 (CNT3) gene was significantly higher in t(8;21)-positive patients compared to the others in the test population and the validation cohort (P<0.001 in Mann-Whitney U test; P<0.002 in Pearson's correlation analysis). Additionally, in both multivariate and univariate analyses, t(8;21)-positive patients categorized in a higher CNT3 expression tertile had longer disease-free survival [hazard ratio (HR), 0.117; 95% confidence interval (CI), 0.025-0.557; P= 0.008] and overall survival (HR, 0.062; 95% CI, 0.007-0.521; P=0.010) compared to t(8;21)-positive patients in a lower CNT3 expression tertile. Notably, these trends did not occur in t(8;21)-negative patients. Our results demonstrate that CNT3 expression is associated with overall favorable outcomes and is predictive of clinical outcomes in AML patients with t(8;21). This suggests that CNT3 expression can be used to optimize treatment strategies for AML patients.
Introduction
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy that displays diverse responses to chemotherapy. Although a number of clinical factors affect treatment outcomes, the cytogenetic features of AML are generally accepted as strong predictors of therapeutic response (1) . Pediatric and adult patients carrying the t(8;21) chromosomal translocation, which is one of the most frequent AML subtypes, are part of a favorable risk group (2) . Although these patients are initially highly responsive to treatment, a number of patients relapse and fail to achieve long-term disease-free survival (DFS) (3) (4) (5) . However, little is currently known concerning the functional mechanism by which t(8;21) is associated with both a higher remission rate in some patients, and occasionally with poor outcomes in others, except in cases that are characterized by other factors such as distinctive immunophenotypical changes and multidrug resistance genes (6) (7) (8) .
Cytarabine is a nucleoside analog that is intensively used for the treatment of AML (9) (10) (11) . Because of its hydrophilic nature, cytarabine can only enter cells via nucleoside transporters such as concentrative nucleoside transporters (CNT1/2/3) and equilibrative nucleoside transporters (ENT1/2) (12, 13) . Cytarabine must also be converted to its active form by specific enzymes such as deoxycytidine kinase (dCK) (14) . Several groups have reported that low gene expression and protein activity of these factors confers resistance to nucleoside drugs of leukemia cells in in vivo and in vitro studies (15) (16) (17) (18) . Alternatively, activation of certain components of the metabolic machinery such as cytidine deaminase (CDA), ecto-5'-nucleotidase (CD73) and 5',3'-nucleotidase (NT5C), may cause resistance to cytarabine therapy (19) (20) (21) (22) . Microarray analysis of an in vitro gemcitabine-resistant model revealed upregulation of ribonucleotide reductase M subunits (RRM1/2) as part of the intracellular detoxification process (23) . Nevertheless, the prognostic implications of changes in the expression of these genes have not been elucidated in specific subpopulations, such as in AML patients with t(8;21).
Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy
In the present study, we hypothesized that specific genes that are closely involved in the antitumor action of cytarabine may be associated with the clinical response to treatment of AML patients carrying t (8;21) . Therefore, we attempted to identify a novel marker that was predictive of outcomes of patients carrying the t(8;21) abnormality and evaluated the prognostic impact of the candidate genes. 2 /day; one patient, daunorubicin plus cytarabine; one patient, cytarabine plus etoposide. Patients who failed to achieve complete remission (CR) after the first round of induction chemotherapy received re-induction chemotherapy with the same regimen. Patients achieving a CR received 3 courses of high-dose Ara-C (3 g/m 2 every 12 h/ day on days 1, 3 and 5) or the combination of idarubicin and BH-AC for consolidation therapy. Thirty-three patients in the test cohort and 13 patients in the validation cohort received hematopoietic stem cell transplantation (HSCT).
Materials and methods

Patient
RNA preparation and real-time polymerase chain reaction (real-time PCR)
. Total RNA was extracted from the BM-MNCs of patients using the Qiagen RNA isolation kit (Qiagen, Venlo, The Netherlands) and converted to cDNA with a reverse transcription kit (Invitrogen, Carlsbad, CA, USA). The cDNA was mixed with SYBR-Green PCR Master Mix (PE Applied Biosystems, Foster City, CA, USA) and specific primers for 8 genes including CD73, CDA, NT5C, dCK, CNT3, ENT1, RRM1 and RRM2. Amplification reactions were performed in triplicate using the ABI Prism 7900 Sequence Detection system (PE Applied Biosystems). GAPDH served as an experimental control. Primer sequences, PCR conditions, and data processing were previously described (24) . In the validation study, the expression levels of the membrane transporters, CNT1, CNT2, CNT3, ENT1 and ENT2, were evaluated by the method described above. However, we excluded the results for CNT1 and CNT2 from further analysis because they had low or undetectable signals that were not as reliable.
Survival estimate and correlation analyses.
The study population was separated based on the cytogenetic abnormalities of the patients. For the purpose of statistical analysis of the target gene, the patients were also subdivided into 3 groups (low, intermediate and high) according to candidate gene expression tertiles. DFS was defined as the time from first remission to relapse or death. Overall survival (OS) was defined as the time from diagnosis to the date of death or last followup. Kaplan-Meier estimates were used to construct survival curves. Statistical differences in the treatment outcomes were determined by the univariate analyses with log-rank test and Cox proportional hazards univariate model. In multivariate analysis, a backward stepwise method of Cox proportional hazards model was used to investigate the association of clinical variables and gene expression pattern with DFS and OS and to assess hazard ratio (HR) with 95% confidence interval (CI). Correlations between clinical and molecular features were obtained by Pearson's correlation statistics and represented as a correlation coefficient (r). All statistical analyses were performed using SPSS version 12.0 (SPSS, Inc., Chicago, IL, USA).
Results
Prolonged survival in patients carrying t(8;21).
We collected BM-MNCs from 54 newly diagnosed patients with M2 subtype AML according to the FAB classification who received cytarabine-based chemotherapy. Although it is well established that AML patients with the t(8;21) abnormality respond better to chemotherapy than patients with normal cytogenetics or other cytogenetic abnormalities (1,2,25), we confirmed this in our study population. In a univariate analysis, Kaplan-Meier estimates showed longer survival rates in terms of DFS (P= 0.028 in log-rank; P= 0.037 in Cox model) and OS (P= 0.029 in log-rank; P= 0.034 in Cox model) in the t(8;21)-positive AML cohort compared to the t(8;21)-negative group (Fig. 1) . Fig. 2A ).
To further clarify the distinctive expression patterns of CNT3 in patients, we divided the patients into 3 groups: t(8;21) (n=25), normal cytogenetics (n=16), and other cytogenetic abnormalities (n=13). The patients carrying t(8;21) still had higher CNT3 expression compared to either of the other patient groups, even though the t(8;21)-negative population was divided into 2 subpopulations (Fig. 2B) .
The t(8;21) abnormality-specific increase in CNT3 expression was confirmed in a validation cohort of 44 patients diagnosed with M2 FAB subtype AML. To further examine the association between nucleoside transporter genes and cytogenetic abnormalities, we analyzed expression levels of solute carrier (SLC) family genes, including SLC28 (CNT1, CNT2 and CNT3) and SLC29 (ENT1 and ENT2). The levels of CNT1 and CNT2 mRNA were low or undetectable in most of the validation cohort and, therefore, results for these genes were excluded from the following analysis. As shown in Fig. 3A , we observed that CNT3 expression was significantly elevated in patient samples that were t(8;21)-positive, compared to those that were t(8; 0.47 (0.04-5.12) for t(8;21)-negative patients. Levels of ENT1 and ENT2 were not statistically different between the two groups. We also compared DFS and OS between t(8;21)-positive and -negative patient groups. Prolonged survival was observed in patients harboring t(8;21), although the results did not reach statistical significance for survival indices (P=0.342 for DFS and P= 0.250 for OS in log-rank tests; Fig. 3B ). The t(8;21)-specific higher expression of CNT3 was consistent with the observation in Fig. 2 and implies a particular contribution of CNT3 to favorable outcomes of these patients.
Prognostic impact of CNT3 expression on treatment outcomes.
We hypothesized that expression of CNT3 in patients with t(8;21) could enable more precise prediction of treatment outcomes. To examine the potential role of CNT3 in predicting outcomes, 45 t(8;21)-positive patients from the test and validation cohorts were clustered into 3 groups (tertiles) based on their levels of CNT3 expression (high, intermediate or low). First, the prognostic impact of CNT3 was evaluated by univariate analysis. As shown in Fig. 4 , patients with high CNT3 expression had significantly longer survival compared to the other two patient groups (DFS, P= 0.008; OS, P= 0.019 in log-rank tests). In a Cox proportional hazards univariate model, HRs for the patients in the high CNT3 tertile compared to the patients in the low tertile were 0.18 (95% CI, 0.05-0.63; P= 0.008) for DFS and 0.14 (95% CI, 0.03-0.66; P= 0.013) for OS. However, when the prognostic value of CNT3 was investigated in a separate, restricted group of patients lacking the t(8;21), there were no significant differences in survival among the subpopulations with different CNT3 expression levels (data not shown).
We conducted a multivariate analysis using the Cox proportional hazards model, which adjusted for the influence of the remission induction (RI) regimen, hematopoietic stem cell transplantation (HSCT), blast percentage, age, gender and CNT3 mRNA; this model confirmed that high CNT3 expression , and high (n=15; CNT3 ≥3.37). The curves for DFS and OS were generated using Kaplan-Meier estimates. P-values were determined using log-rank tests and univariate Cox regression analysis.
was an independent risk factor associated with DFS (HR, 0.12; P=0.007) and OS (HR, 0.06; P=0.010) (Table II) . Alternatively, clinical outcomes of patients with t(8;21)-negative AML were affected by the RI regimen and HSCT, but not by the CNT3 expression status (data not shown). These findings suggest that CNT3 expression levels can be used to stratify overall clinical outcomes after cytarabine-based standard chemotherapy in AML patients with t(8;21).
Discussion
We showed that cytogenetic abnormality-specific expression of CNT3 in leukemic blasts from AML patients correlated with favorable responses to cytarabine-based chemotherapy and prolonged survival of patients with t(8;21). We also found that CNT3 expression level was an independent predictor of the response to cytarabine-based chemotherapy in the t(8;21)-positive AML patients.
The t(8;21) translocation is one of the most frequent cytogenetic abnormalities, occurring in a large proportion (up to 15%) of AML patients. This type of AML has a high remission rate to chemotherapy, particularly when high-dose cytarabine is administered (2, 9, 26) . Nevertheless, some patients with t(8;21) experience relapse and fail to maintain long-term survival (3) (4) (5) . For this reason, most studies concerning the treatment response in AML with t(8;21) have been devoted to identification of useful markers that can be measured at diagnosis to predict poor outcomes. Representative clinically significant examples include the association of natural killer cell antigen CD56 and P-glycoprotein with inferior outcomes in t(8;21)-positive AML patients (6) (7) (8) 27 ). However, neither of these factors is linked with favorable outcomes in patients carrying this aberration. Although a limited number of patients were examined in the present study, we were able to provide the first example of a gene related to cytarabine metabolism that can explain the varied responses of these patients to cytarabine therapy.
Nucleoside transporters including both influx and efflux pumps and drug metabolism-associated enzymes have been steadily identified as predictive markers of clinical outcomes and as potential therapeutic targets (24, (28) (29) (30) (31) . In this study, we examined two types of specialized influx pumps of nucleoside analogs, ENTs and CNTs, as potential candidates for predicting patient outcomes. We chose these transporters because of previous reports indicating that they have a broad spectrum of substrate flux and are predominantly expressed in BM cells (32) (33) (34) . CNT3 expression significantly correlated with the presence of the t(8;21) aberration in both the test and validation data sets. Previous reports indicated that ENT1 was clinically significant for cytarabine-mediated therapy; however, the present study found a slight but insignificant correlation between ENT1 and the t(8;21) translocation in Table II . Multivariate analysis of clinical outcomes in the t(8;21)-positive patients.
Disease-free survival
Overall survival correlation analysis and survival analysis in AML patients with t(8;21) (33, 35, 36) . These results indicate that CNT3, but not ENT1 or other functional genes, is a specific marker of cytogenetics in AML and is also a critical factor in the responsiveness of t(8;21)-positive patients to cytarabine. Nucleoside transporters are required not only for nucleotide synthesis, but also for import of a variety of nucleoside-derived anticancer drugs. Specifically, CNT3 plays a role in the uptake of a broad range of nucleosides and their analogs, while CNT1 and CNT2 are responsible for specialized substrates (pyrimidine and purine nucleosides for CNT1 and CNT2, respectively) (34) . Most studies that have only analyzed CNT3 have used in vitro assays to identify a critical role of CNT3 in the antitumor effect of nucleoside drugs and the resistance to these drugs (34, 37, 38) . Alternatively, a study by Mackey et al (30) showed a negative correlation between CNT3 and clinical outcomes after fludarabine therapy in patients with chronic lymphocytic leukemia. Furthermore, distinct expression of CNT3 has not been reported in AML with specific cytogenetics, even though there were several genome-wide approaches to dissect gene profiles in large numbers of patients (39) (40) (41) . The present study is the first to demonstrate that CNT3 levels can be used to stratify patients based on survival outcomes in, at least in part, t(8;21)-positive but not t(8;21)-negative AML patients. We questioned why the prognostic potential of CNT3 preferentially applied to t(8;21)-positive AML patients. For the survival analysis, we divided t(8;21)-positive or -negative patients into subpopulations based on their CNT3 expression level. The median values for CNT3 expression were 2.07 (range, 0.36-15.76) for the t(8;21)-positive cohort and 0.56 (range, 0.04-5.12) for the t(8;21)-negative cohort. One potential explanation for this observation is that, at least in the t(8;21)-negative population, the small range of CNT3 expression might be insufficient to allow stratification for outcome prediction. Although we did not determine whether CNT3 transcript levels were consistent with protein expression levels in individual patients, and we did not ensure that the protein encoded by the CNT3 gene was functional, it is believed that low mRNA levels are indicative of low CNT3 protein levels, which are insufficient for CNT3 to carry out its novel function.
In the CNT nucleoside transporter family, expression levels of CNT1 and CNT2 are known to be upregulated by extracellular stimuli including cell proliferation and activation (42) (43) (44) . However, the mechanism of transcriptional regulation of CNT3 remains largely unknown. Based on our novel finding that CNT3 was upregulated in AML patients with t(8;21) but not in patients with other cytogenetic changes, we hypothesize that there may be a physiological interaction between the AML1 or AML1-ETO chimera proteins, which are derived from the t(8;21) translocation, and the promoter region of CNT3. Indeed, a virtual analysis for promoter prediction performed using transcription factor binding site search software identified 3 putative binding sites for AML1 at -3438 to -3433, -888 to -883, and +526 to +531 relative to the transcription start site of CNT3. Therefore, additional study is necessary to identify a role of these putative binding sites.
In summary, our results imply that higher CNT3 expression in AML patients with t(8;21) contributes to the prolonged survival observed in this population. Our results also suggest that CNT3 can be used to predict clinical responses to cytarabine-based therapies in AML patients with t(8;21).
